Notification Side Effects
Privacy Policy for Pharmacovigilance Reports
(Art. 13 and 14 of EU Regulation 2016/679)
Dear Reporter,
Pursuant to EU Regulation 2016/679 (“GDPR”) relating to the protection of individuals with regard to the processing of personal data, the following companies of ADIENNE Group ADIENNE SRL, a single-member company with registered office in Caponago (MB), Via Galileo Galilei 19, Italy, and ADIENNE SA, with registered office in Lugano, Via Zurigo 46, Switzerland, each of which acting as joint Data Controller of the data provided by you with your adverse event notification, shall process the above-mentioned data as detailed below.
- Purpose and Legal Basis of Data Treatment
The personal data processed by ADIENNE SRL and ADIENNE SA is those provided by you with your adverse event notification relating to a marketed medicinal product owned by ADIENNE SRL or ADIENNE SA, i.e. (i) your personal data as Reporter (including but not limited to your first name, last name, telephone number, e-mail address, qualification) and (ii) personal data of the subject who has been treated with a medicinal product owned by ADIENNE SRL or ADIENNE SA (including but not limited to their first name, last name, sex, age, weight, state of health) and who has suffered adverse drug reactions/effects as reported by you. The subject’s name shall always be anonymized and replaced by their initials. The above-mentioned data shall be processed by each Company for the purposes of: a) complying with the pharmacovigilance obligations(*) laid down by GVP (Good Pharmacovigilance Practices) such as for example: (i) to detect any unknown adverse reactions/effects; (ii) to improve and increase information available on the suspected adverse reactions/effects that are already known; (iii) to report to the competent Authority(ies); (iv) to monitor the risk-benefit balance and ensure that it remains favorable to the population. b) protecting interests in judicial settings in the event of any disputes relating to the notification made or the use of the medicinal product for which a notification has been made. For the purposes of this Policy, the term “Treatment” refers to any and all operations described under Art. 4. n° 2 of GDPR, i.e.: the collection, record, organization, retention, consultation, processing, modification, selection, extraction, comparison, use, networking, blocking, communication, deletion, and destruction of data.
- Modalities of Data
Processing and Data Retention Period Data shall be processed in a lawful, correct and transparent manner, in accordance with the principles of necessity, lawfulness, proportionality, and purpose. The Treatment shall be performed by means of paper-based and/or computer tools, along with automated instruments designed to record and process the data, and in accordance with the provisions under Art. 29 of GDPR 2016/679. Data shall be treated for no longer than it is strictly necessary for the purposes for which they are collected and processed, i.e.:
– for the purposes under 1 (a) for as long as the medicinal product used has a Marketing Authorization (MA) in place and for 10 years thereafter, unless otherwise required by the competent regulatory authorities;
– for the purposes under 1 (b) at all times during the judicial proceeding and for the subsequent 5 years.
- Communication and Disclosure of Data
Your personal data may be made available (I) by ADIENNE SRL: for the purposes under 1. to those Company’s employees who have a need to take charge of and process the notification received, and who have been authorized to process the data, to the sister company ADIENNE SA, to the Competent Authorities to which the adverse event report is to be transmitted in order to comply with the GVP obligations, to the other Competent Authorities that need to acquire the data, to the legal, tax, administrative, medical, IT consultants and service providers that have entered into a proper agreement with the Company (e.g. providers of services for the management of report collection and processing systems, electronic data storage and document archiving, acting on our behalf as Data Treatment Managers by way of specific contractual agreements); (II) by ADIENNE SA: for the purposes under 1. to those Company’s employees who have a need to take charge of and process the report received, and who have been authorized to process the data, to the sister company ADIENNE SRL, to the Competent Authorities to which the adverse event report is to be transmitted in order to comply with the GVP obligations, to the other Competent Authorities that need to acquire the data, to the legal, tax, administrative, medical, IT advisors and service providers that have entered into a proper agreement with the Company (e.g. providers of services for the management of report collection and processing systems, electronic data storage and document archiving, acting on our behalf as Data Treatment Managers by way of specific contractual agreements). The subjects to whom the personal data has been disclosed shall act either as independent Data Controllers, or as duly appointed Joint Data Controllers or External Data Processors, in accordance with GDPR provisions.
- Transfer of Data to Third Countries
The personal data processed by the Companies may be transferred outside the European Union, to Countries to which the European Commission has issued a positive opinion with regard to data protection adequacy and to Countries where this adequacy has not been acknowledged. However, it is made clear that personal data shall be transferred to Regulatory Authorities and to Advisors/Service Providers which the Companies avail themselves of in order to comply with the obligations under pharmacovigilance regulations, and all appropriate safety measures shall always be taken with regard to the transfer of personal data. A full list of Countries where data may be transferred to is available from the Companies.
- Nature of Data Provision
The provision of personal data under 1. is mandatory, as any refusal to provide said personal data would prevent ADIENNE SRL and ADIENNE SA from complying with the regulatory pharmacovigilance obligations.
- Data Subject’s Rights
As Data Subject, you can exercise the following rights pursuant to Art. 15 to 22 of GDPR:
‐ to obtain confirmation of the existence of any of your personal data;
‐ to obtain information regarding the purposes of processing, the categories of personal data, the subjects or categories of subjects to whom the data has been or may be disclosed, and the period of data retention, if applicable;
‐ to have your personal data edited or deleted;
‐ to obtain data treatment limitation;
‐ to obtain data portability, i.e. to receive your data from a Data Controller in a structured and commonly used format readable by any automated device, and transfer said data to another Data Controller without hindrance;
‐ to object at any time to the processing of your personal data, including the processing for direct marketing purposes;
‐ to object to any automated decision-making procedure relating to individuals, including profiling;
‐ to request to the Data Controller access to, rectification or deletion of your personal data, treatment limitation or objection to the processing of your data, along with the right to data portability;
‐ to withdraw your consent at any time without prejudice to the lawfulness of the processing based on consent before its withdrawal;
‐ to submit a claim to a Supervisory Authority.
You may exercise your rights by sending a written request to the following e-mail addresses:
To ADIENNE SRL: privacy@adienne.com
To ADIENNE SA: privacyadiennesa@adienne.com
(*)Pharmacovigilance includes a set of activities involving the Competent Authorities, the Marketing Authorization Holders, local healthcare facilities and healthcare professionals. The contribution of individuals is essential to ensure the proper functioning of pharmacovigilance mechanisms. From a pharmacovigilance point of view, the Marketing Authorization Holder is required by law to record and assess in detail any suspected adverse reactions occurred in relation to their medicinal products, with the aim to safeguard consumer health. A spontaneous notification is a notice from a healthcare professional or a patient/consumer relating to an adverse reaction or effect which is suspected to have occurred after intake of a medicinal product. Such notification allows pharmaceutical companies to detect any warning signals relating to their marketed products. The quality and completeness of the information collected with the spontaneous notification are of the essence to ensure the effective functioning of the pharmacovigilance system. The quality of information depends on the level of consistency, completeness and precision of the data reported. Incomplete notifications may not allow to assess the causal link between the product concerned and the event occurred and thus detect a possible warning signal relating to safety.
